Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioFRA:1IJ +2.74%35 Buyback Yield % is 0.00 as of Jul. 24, 2026. GuruFocus rates FRA:1IJ with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 738 Biotechnology companies, Adicet Bio ranks worse than 135501.22% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Adicet Bio's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1IJ vs EDSA, GOSS, HRTX: Buyback Yield % Comparison
For the Biotechnology subindustry, Adicet Bio's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (FRA:1IJ) has a Buyback Yield % of 0.00 as of Jul. 24, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Adicet Bio and its competitors. According to the industry distribution chart, Adicet Bio ranks #999999 out of 738 companies in the Biotechnology industry.
Is Adicet Bio's Buyback Yield % too high?
Adicet Bio's current Buyback Yield % is 0.00. Based on the distribution chart, Adicet Bio ranks #999999 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adicet Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Buyback Yield % compare to EDSA and GOSS?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #999999 out of 738 companies for Buyback Yield %. This places Adicet Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Adicet Bio and its competitors. Adicet Bio's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Adicet Bio's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current Buyback Yield % is 0.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
35GF Score
Get the complete analysis for FRA:1IJ
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1IJ has been successfully added to your 
